Synergy-Guided Molecular Redesign of Predicted P-Glycoprotein Substrates toward Synthetically Feasible Non-Substrates
Journal of Chemical Information and Modeling · 09.11.2026 · 66 (21) · 14174-14187
DOI: 10.1021/acs.jcim.6c01938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, online erschienen am 19.10.2026. Verfasst von Soyeon Jeon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju61005, Republic of Korea. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Drug Design. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea, National Research Council of Science and Technology.
Abstract (Originalsprache)
Drug efflux mediated by P-glycoprotein (P-gp) remains a major barrier to effective small-molecule therapeutics, limiting both bioavailability and central nervous system exposure. While machine learning models can predict P-gp substrates, translating these predictions into actionable molecular design remains largely unexplored, particularly in enabling the rational conversion of substrates into nonsubstrates to mitigate efflux liability. Here, we introduce the synergy-guided fragment genetic algorithm (SF-GA), a computational framework that transforms predictive insight into an interpretable molecular design strategy. By integrating fragment synergy analysis into the mutation stage of a genetic algorithm, SF-GA biases fragment replacement toward co-occurring substructures associated with nonsubstrate classification, enabling interpretability at the chemical structure level and property-directed molecular optimization. Compared with genetic-algorithm and reinforcement-learning baselines under a fixed function-evaluation budget, SF-GA achieves competitive optimization performance while producing molecules with the highest retrosynthetic accessibility among all methods tested. Unlike the baselines, every accepted mutation is reported together with the discarded and inserted fragments and their synergy scores, providing a fragment-level rationale for each structural change; ablation against an unguided and an importance-only control isolates the contribution of bit co-occurrence. The method enables scaffold-preserving and similarity-constrained editing that converts P-gp substrates into predicted nonsubstrates. Docking against two human P-gp structures reveals weaker predicted binding for molecules with higher predicted nonsubstrate probability, motivating future experimental evaluation of P-gp transport.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju61005, Republic of Korea.
- Center for Quantum Technology, Korea Institute of Science and Technology, Seoul02792, Republic of Korea.
ORCID-Profile: Hyun Woo Kim
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- National Research Council of Science and Technology
Zitieren
APA
Jeon, S., Moon, S. W., & Kim, H. W. (2026). Synergy-Guided Molecular Redesign of Predicted P-Glycoprotein Substrates toward Synthetically Feasible Non-Substrates. Journal of Chemical Information and Modeling, 66(21), 14174-14187. https://doi.org/10.1021/acs.jcim.6c01938
Vancouver
Jeon S, Moon SW, Kim HW. Synergy-Guided Molecular Redesign of Predicted P-Glycoprotein Substrates toward Synthetically Feasible Non-Substrates. Journal of Chemical Information and Modeling. 2026;66(21):14174-14187. doi:10.1021/acs.jcim.6c01938
BibTeX
@article{Jeon2026,
author = {Jeon, Soyeon and Moon, Sung Wook and Kim, Hyun Woo},
title = {Synergy-Guided Molecular Redesign of Predicted P-Glycoprotein Substrates toward Synthetically Feasible Non-Substrates},
journal = {Journal of Chemical Information and Modeling},
year = {2026},
volume = {66},
number = {21},
pages = {14174--14187},
doi = {10.1021/acs.jcim.6c01938}
}
EUVIMED